Methoclocinnamox: time course of changes in alfentanil-reinforced responding in rhesus monkeys
dc.contributor.author | Winger, Gail D. | en_US |
dc.contributor.author | Woods, James H. | en_US |
dc.contributor.author | Lewis, James W. | en_US |
dc.contributor.author | Briscoe, Richard J. | en_US |
dc.date.accessioned | 2006-09-08T19:49:56Z | |
dc.date.available | 2006-09-08T19:49:56Z | |
dc.date.issued | 2000-03 | en_US |
dc.identifier.citation | Briscoe, R. J.; Winger, G.; Lewis, J. W.; Woods, J. H.; (2000). "Methoclocinnamox: time course of changes in alfentanil-reinforced responding in rhesus monkeys." Psychopharmacology 148(4): 393-399. <http://hdl.handle.net/2027.42/41970> | en_US |
dc.identifier.issn | 0033-3158 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/41970 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10928312&dopt=citation | en_US |
dc.description.abstract | Rationale : Methoclocinnamox (MC-CAM) possesses initial partial µ-opioid agonist activity with subsequent long-lasting µ-antagonist effects. This profile of activity is similar to that of buprenorphine, a compound with proposed use in the treatment of opioid abuse, suggesting a possible therapeutic use for MC-CAM as well. Objective : The current study assessed the time course of the ability of MC-CAM and buprenorphine to antagonize the reinforcing effects of alfentanil and compared this with that of buprenorphine. Methods : Rhesus monkeys self-administered a range of doses of alfentanil (0.03–1 µg/kg per injection) under a fixed-ratio 30, time-out 45 s schedule of i.v. drug delivery. MC-CAM was substituted for alfentanil on occasion, and a dose of 1.0 mg/kg MC-CAM or buprenorphine was given prior to sessions in which alfentanil was available. In the pretreatment studies, a wider range of alfentanil doses was utilized (0.03–30 µg/kg per injection). Results : MC-CAM maintained self-administration behavior and was nearly equipotent with buprenorphine as a reinforcer in this para digm. Both drugs, when given prior to a session in which alfentanil was available, produced a decrease in the reinforcing potency of alfentanil. The antagonist effects of the pretreatments were largest 30 min following administration and decreased over the next several days. The duration of MC-CAM’s antagonism of alfentanil was approximately 4 days; the duration of buprenorphine as an antagonist was approximately 2 days. Conclusion : These data suggest that MC-CAM has a longer duration of antagonist effects than buprenorphine and it may therefore have an advantage in the treatment of opioid abuse. | en_US |
dc.format.extent | 72831 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag Berlin Heidelberg | en_US |
dc.subject.other | Operant Responding | en_US |
dc.subject.other | Methoclocinnamox | en_US |
dc.subject.other | Opioid Receptor | en_US |
dc.subject.other | Key Words Alfentanil | en_US |
dc.subject.other | Self-administration | en_US |
dc.subject.other | Time Course | en_US |
dc.subject.other | Legacy | en_US |
dc.subject.other | Buprenorphine | en_US |
dc.title | Methoclocinnamox: time course of changes in alfentanil-reinforced responding in rhesus monkeys | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmacology, University of Michigan, 1301 Medical Science Research Building III, Ann Arbor, MI 48109-0632, USA e-mail: gwinger@umich.edu, Fax: +1-734-7649118, US, | en_US |
dc.contributor.affiliationum | Department of Pharmacology, University of Michigan, 1301 Medical Science Research Building III, Ann Arbor, MI 48109-0632, USA e-mail: gwinger@umich.edu, Fax: +1-734-7649118, US, | en_US |
dc.contributor.affiliationum | Department of Pharmacology, University of Michigan, 1301 Medical Science Research Building III, Ann Arbor, MI 48109-0632, USA e-mail: gwinger@umich.edu, Fax: +1-734-7649118, US, | en_US |
dc.contributor.affiliationother | Department of Chemistry, University of Bristol, Bristol, UK, GB, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 10928312 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/41970/1/213-148-4-393_01480393.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s002130050068 | en_US |
dc.identifier.source | Psychopharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.